EML4 and cancer: Furthermore, inhibition of EML4-ALK with crizotinib in H3122 patient-derived cancer cells suppressed not only wild-type RAS-GTP levels, but also the levels of GTP-bound, cytosolic KRAS-C185S (Figures 3C, 3D, S3M, and S3N).